James A. Schoeneck Acquires 250,000 Shares of FibroGen, Inc. (NASDAQ:FGEN) Stock

FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck acquired 250,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was purchased at an average price of $0.35 per share, with a total value of $87,500.00. Following the completion of the acquisition, the director now directly owns 323,722 shares in the company, valued at approximately $113,302.70. This represents a 339.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

FibroGen Trading Down 7.2 %

NASDAQ FGEN opened at $0.34 on Wednesday. The firm has a market cap of $34.57 million, a PE ratio of -0.28 and a beta of 0.82. FibroGen, Inc. has a 1-year low of $0.18 and a 1-year high of $2.79. The stock has a 50-day moving average of $0.48 and a 200-day moving average of $0.43.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $24.91 million. As a group, equities research analysts forecast that FibroGen, Inc. will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in shares of FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares during the period. JPMorgan Chase & Co. lifted its holdings in FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after buying an additional 1,358,194 shares during the period. FMR LLC grew its position in shares of FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares during the last quarter. Franklin Street Advisors Inc. NC increased its stake in shares of FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 100,000 shares during the period. Finally, Two Sigma Investments LP raised its holdings in shares of FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock valued at $320,000 after acquiring an additional 98,888 shares in the last quarter. Institutional investors own 72.71% of the company’s stock.

Analyst Upgrades and Downgrades

FGEN has been the subject of a number of recent research reports. StockNews.com began coverage on FibroGen in a research report on Saturday. They issued a “hold” rating for the company. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a report on Tuesday, March 18th.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.